Gelişimsel Ensefalopati
Özet
Gelişimsel ensefalopati, otizm spektrum bozukluğu ve zihinsel yetersizlik ile örtüşen ancak bu tanımlara tam uymayan; epileptik nöbetler, solunum ve gastrointestinal sorunlar gibi birden fazla sistem tutulumuyla seyreden nörogelişimsel bir bozukluk grubudur. Bu tablolar genellikle spesifik genetik mutasyonlara dayanır ve nöronal gelişim yollarındaki kritik bozulmalarla karakterize edilir. Rett, Angelman, CDKL5 ve FOXG1 gibi sendromlar bu grupta yer alarak hem epileptik nöbetlerin hem de gelişimsel geriliklerin yönetilmesinde karmaşık klinik süreçleri beraberinde getirir. İleri genetik tanı yöntemlerinin kullanılması, bu karmaşık bozuklukların altında yatan mekanizmaların aydınlatılmasını sağlayarak hem tıbbi komplikasyonların takibinde hem de kişiselleştirilmiş tedavi kararlarının verilmesinde hayati bir rol oynamaktadır.
Developmental encephalopathy describes a group of neurodevelopmental disorders that partially overlap with autism spectrum disorders and intellectual disabilities but do not fit traditional classifications due to the presence of systemic issues like epileptic seizures, respiratory dysfunction, and gastrointestinal complications. These conditions are typically driven by specific genetic mutations that disrupt critical neuronal development pathways. Syndromes such as Rett, Angelman, CDKL5, and FOXG1 highlight the complex clinical management required for both seizures and developmental delays within this category. The increasing use of advanced genetic diagnostics is crucial for uncovering underlying pathological mechanisms, which significantly aids in managing medical complications and tailoring treatment decisions for affected individuals.
Referanslar
Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005- 2009. Epilepsia 2010;51:676–85.
Seltzer LE, Ma M, Ahmed S, et al. Epilepsy and outcome in FOXG1-related disorders. Epilepsia 2014;55(8):1292–300.
Strømme P, Mangelsdorf ME, Scheffer IE, et al. Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in Aristaless related homeobox gene, ARX. Brain Dev 2002; 24:266–8.
Steffenburg S, Gillberg CL, Steffenburg U, et al. Autism in Angelman syndrome: a population-based study. Pediatr Neurol 1996; 14:131–6.
Young DJ, Bebbington A, Anderson A, et al. The diagnosis of autism in a female: could it be Rett syndrome? Eur J Pediatr 2008;167:661–9.
Ramirez J-M, Ward CS, Neul JL. Breathing challenges in Rett syndrome: lessons learned from humans and animal models. Respir Physiol Neurobiol 2013;189:280–7.
De Felice C, Maffei S, Signorini C, et al. Subclinical myocardial dysfunction in Rett syndrome. Eur Heart J Cardiovasc Imaging 2012;13:339–45.
Valente KD, Koiffmann CP, Fridman C, et al. Epilepsy in patients with angelman syndrome caused by deletion of the chromosome 15q11-13. Arch Neurol 2006;63:122–8.
American Psychiatric Association, American Psychiatric Association, and DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. Arlington, Va.: American Psychiatric Association; 2013.
Gold WA, Krishnarajy R, Ellaway C, Christodoulou J. Rett Syndrome: A Genetic Update and Clinical Review Focusing on Comorbidities. ACS Chem Neurosci. 2018 Feb 21;9(2):167-176..
Spagnoli C, Fusco C, Pisani F. Rett Syndrome Spectrum in Monogenic Developmental-Epileptic Encephalopathies and Epilepsies: A Review. Genes (Basel). 2021;12(8):1157. Published 2021 Jul 28. doi:10.3390/genes12081157
Dolce A, Ben-Zeev B, Naidu S, et al. Rett syndrome and epilepsy: an update for child neurologists. Pediatr Neurol 2013;48: 337–45.
Weaving LS, Christodoulou J, Williamson SL, et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am.J Hum. Genet 2004;75(6):1079–1093
Olson HE, Demarest ST, Pestana-Knight EM, et al. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: Clinical Review. Pediatr Neurol. 2019;97:18-25.
Olson HE, Demarest S, Pestana-Knight E, Benke TA. Clinical experience with CDKL5 Deficiency Disorder in the Centers of Excellence. Unpublished data. 2018.
Fehr S, Wong K, Chin R, et al. Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. Neurology. 2016;87(21):2206–2213.
Fehr S, Wilson M, Downs J, et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet. 2013;21(3):266–273.
Mangatt M, Wong K, Anderson B, et al. Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome. Orphanet J Rare Dis. 2016;11:39.
Hébert JM, Fishell G. The genetics of early telencephalon patterning: some assembly required. Nat Rev Neurosci 2008;9: 678–85.
Brancaccio M, Pivetta C, Granzotto M, et al. Emx2 and Foxg1 inhibit gliogenesis and promote neuronogenesis. Stem Cells 2010;28:1206–18.
Kortüm F, Das S, Flindt M, et al. The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med Genet 2011;48:396–406.
Le Meur N, Holder-Espinasse M, Jaillard S, et al. MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malforma- tions. J Med Genet 2010;47:22–9.
Zweier M, Rauch A. The MEF2C-Related and 5q14.3q15 Micro- deletion Syndrome. Mol Syndromol. 2012;2:164–70.
Paciorkowski AR, Traylor RN, Rosenfeld JA, et al. MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways. Neurogenetics 2013;14:99–111.
Goodspeed K, Newsom C, Morris MA, Powell C, Evans P, Golla S. Pitt-Hopkins Syndrome: A Review of Current Literature, Clinical Approach, and 23-Patient Case Series. J Child Neurol. 2018;33(3):233-244. doi:10.1177/0883073817750490
Marangi G, Ricciardi S, Orteschi D, et al. The Pitt-Hopkins syndrome: report of 16 new patients and clinical diagnostic criteria. Am J Med Genet A 2011;155A:1536–45.
Rosenfeld JA, Leppig K, Ballif BC, et al. Genotype-phenotype analysis of TCF4 mutations causing Pitt-Hopkins syndrome shows increased seizure activity with missense mutations. Genet Med 2009;11:797–805.
Zweier C, Sticht H, Bijlsma EK, et al. Further delineation of Pitt-Hopkins syndrome: phenotypic and genotypic description of 16 novel patients. J Med Genet 2008;45:738–44.
Mowat DR, Wilson MJ, Goossens M. Mowat-Wilson syndrome. J Med Genet 2003;40:305–10.
Adam MP, Schelley S, Gallagher R, et al. Clinical features and management issues in Mowat-Wilson syndrome. Am J Med Genet A 2006;140:2730–41.
Cordelli DM, Garavelli L, Savasta S, et al. Epilepsy in Mowat- Wilson syndrome: delineation of the electroclinical phenotype. Am J Med Genet A 2013;161A:273–84.
Evans E, Einfeld S, Mowat D, et al. The behavioral phenotype of Mowat-Wilson syndrome. Am J Med Genet A 2012;158A:358–66.
Tan WH, Bacino CA, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, et al. Angelman syndrome: Mutations influence features in early childhood. Am J Med Genet A. 2011;155A:81–90
Mertz LGB, Christensen R, Vogel I, et al. Angelman syndrome in Denmark. Birth incidence, genetic findings, and age at diagnosis. Am J Med Genet A 2013; 161: 2197–203.
Wheeler AC, Sacco P, Cabo R. Unmet clinical needs and burden in Angelman syndrome: a review of the literature. Orphanet J Rare Dis. 2017;12(1):164.
Gentile JK, Tan W-H, Horowitz LT, et al. A neurodevelopmental survey of Angelman syndrome with genotype-phenotype correlations. J Dev Behav Pediatr 2010;31:592–601.
Larson AM, Shinnick JE, Shaaya EA, et al. Angelman syndrome in adulthood. Am J Med Genet A 2015;167A:331–44.
Takaesu Y, Komada Y, Inoue Y. Melatonin profile and its relation to circadian rhythm sleep disorders in Angelman syndrome patients. Sleep Med 2012;13:1164–70.
Wang TS, Tsai WH, Tsai LP, Wong SB. Clinical characteristics and epilepsy in genomic imprinting disorders: Angelman syndrome and Prader-Willi syndrome. Ci Ji Yi Xue Za Zhi. 2019;32(2):137-144.
Cassidy SB, Driscoll DJ. Prader–Willi syndrome. Eur J Hum Genet 2009;17(1):3-13
Myers SE, Whitman BY, Carrel AL, et al. Two years of growth hormone therapy in young children with Prader-Willi syndrome: physical and neurodevelopmental benefits. Am J Med Genet A 2007;143A:443–8.
Soni S, Whittington J, Holland AJ, et al. The course and outcome of psychiatric illness in people with Prader-Willi syndrome: implications for management and treatment. J Intellect Disabil Res 2007;51:32–42.
Verrotti A, Cusmai R, Laino D, et al. Long-term outcome of epilepsy in patients with Prader-Willi syndrome. J Neurol 2015;262:116–23.
Depienne C, Moreno-De-Luca D, Heron D, et al. Screening for genomic rearrangements and methylation abnormalities of the 15q11-q13 region in autism spectrum disorders. Biol Psychiatry 2009;66:349–59.
Conant KD, Finucane B, Cleary N, et al. A survey of seizures and current treatments in 15q duplication syndrome. Epilepsia 2014;55:396–402.
Gregor A, Albrecht B, Bader I, et al. Expanding the clinical spectrum associated with defects in CNTNAP2 and NRXN1. BMC Med Genet 2011;12:106.
Murdoch JD, Gupta AR, Sanders SJ, et al. No evidence for asso- ciation of autism with rare heterozygous point mutations in Contactin-Associated Protein-Like 2 (CNTNAP2), or in Other Contactin-Associated Proteins or Contactins. PLoS Genet 2015;11:e1004852.
Veerappa AM, Saldanha M, Padakannaya P, et al. Family-based genome-wide copy number scan identifies five new genes of dyslexia involved in dendritic spinal plasticity. J Hum Genet 2013;58:539–47.
Van Bon BWM, Coe BP, Bernier R, et al. Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID. Mol Psychiatry 2015;21(1):126–32.
Ji J, Lee H, Argiropoulos B, et al. DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies. Eur J Hum Genet 2015.
Lalani SR, Zhang J, Schaaf CP, et al. Mutations in PURA cause profound neonatal hypotonia, seizures, and encephalopathy in 5q31.3 microdeletion syndrome. Am J Hum Genet 2014;95: 579–83.
